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Abstract
Tumor cells can escape the immune system by overexpressing molecules of the B7 family, e.g. B7-H1 (PD-L1 or
CD86), which suppresses the anti-tumor T-cell responses through binding to the PD-1 receptor, and similarly for
B7.1 (CD80), through binding to CTLA-4. Moreover, direct interactions between B7-H1 and B7.1 molecules are also
likely to participate in the immunoevasion mechanism. In this study, we used a mouse model of tumor dormancy,
DA1-3b leukemia cells. We previously showed that a minor population of DA1-3b cells persists in equilibrium with
the immune system for long periods of time, and that the levels of surface expression of B7-H1 and B7.1 molecules
correlates with the dormancy time. We found that leukemia cells DA1-3b/d365 cells, which derived from long-term
dormant tumors and overexpressed B7-H1 and B7.1 molecules, were highly permissive to Ad5FB4, a human
adenovirus serotype 5 (Ad5) vector pseudotyped with chimeric human-bovine fibers. Both B7-H1 and B7.1 were
required for Ad5FB4-cell binding and entry, since (i) siRNA silencing of one or the other B7 gene transcript resulted
in a net decrease in the cell binding and Ad5FB4-mediated transduction of DA1-3b/d365; and (ii) plasmid-directed
expression of B7.1 and B7-H1 proteins conferred to Ad5FB4-refractory human cells a full permissiveness to this
vector. Binding data and flow cytometry analysis suggested that B7.1 and B7-H1 molecules played different roles in
Ad5FB4-mediated transduction of DA1-3b/d365, with B7.1 involved in cell attachment of Ad5FB4, and B7-H1 in
Ad5FB4 internalization. BRET analysis showed that B7.1 and B7-H1 formed heterodimeric complexes at the cell
surface, and that Ad5FB4 penton, the viral capsomere carrying the fiber projection, could negatively interfere with
the formation of B7.1/B7-H1 heterodimers, or modify their conformation. As interactors of B7-H1/B7.1 molecules,
Ad5FB4 particles and/or their penton capsomeres represent potential therapeutic agents targeting cancer cells that
had developed immunoevasion mechanisms.
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Background
Tumor cells express numerous molecules at their sur-
face that may influence their recognition by the immune
system. Among them, proteins of the B7 family play
important roles in the immunoevasion of tumor cells
and can suppress T-cell-mediated immunity by binding
to the inhibitory receptor CTLA-4, e.g. B7.1 (or CD80)
and B7.2 (or CD86). Tumor cells that express B7.1 may
be shielded from direct cytotoxic T-cell (CTL)-mediated
killing [1-3]. Other members of the B7 family include
B7-H1 (PD-L1 or CD274), B7-DC (PD-L2), ICOS-L, B7-
H3 and B7-H4, but only B7-H1 and B7-H4 have been
indisputably shown to play a role in the immunoevasion
of cancer cells [4]. B7-H1 binds to its receptor PD-1,
and this binding mediates immunosuppression [5]. B7-
H1 also binds to B7.1 [6], but the function of this inter-
action remains unclear. B7-H1 suppresses the CTL-
mediated killing of tumor cells, induces T-cell anergy
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PD-1 is abundantly expressed on T-cells that infiltrate
the tumor microenvironment. B7-H1 is constitutively
expressed by several human tumors, and is induced
when cancer cells are stimulated with interferon-gIFN-g)
and ligands of Toll-like receptors (TLR) [7-9]. Using a
DA1-3b mouse model of tumor dormancy, we pre-
viously demonstrated that a minor population of dor-
mant leukemia cells persists in equilibrium with the
immune system for long periods of time. Dormant leu-
kemia cells suppressed CTL-mediated killing by overex-
pressing B7-H1 and B7.1 [10-12]. All these observations
suggested that the B7-H1 and B7.1 molecules of the B7-
family could represent potential targets for new antitu-
mor strategies (reviewed in [13]).
Cell surface molecules in cancer cells have been con-
sidered as privileged targets in cancer therapy, but
mostly as targets of therapeutic monoclonal antibodies
(mAb) [14]. Alternative therapeutic methods include the
use of oncolytic viral vectors naturally directed, or
genetically retargeted to specific molecules of the cell
surface, capable of triggering tumor cell death. Recombi-
nant oncolytic adenoviruses offer several advantages
over other oncolytic viral ve c t o r s :( i )t h e yh a v eal a r g e
cloning capacity, (ii) are relatively easy to produce to
high titers, with vector stocks remaining stable over a
long period of storage, and (iii) their therapeutic effects
do not require the viral DNA insertion into the host
genome [15-18]. However, with the exception of certain
members of species B adenoviruses, e.g. HAdV3, which
have the natural ability to bind to B7.1 and B7.2 [19]
and to efficiently transduce B7.1- and B7.2-expressing
malignant glioma cells [20], the usage of adenoviruses in
cancer gene therapy is limited, due to the low level (or
absence) of expression of high affinity receptor for ade-
noviruses in cancer cells, or/and their poor accessibility
at the cell surface. This is the case for the Coxsackie
and Adenovirus human Receptor (hCAR), one of the
natural receptors for adenoviral species A, C, D, E and
F, which is located in the tight junctions and expressed
at low levels in cancer cells [21], and for desmoglein-2,
the receptor of HAdV3, also found in tight junctions
[22]. Different strategies of adenoviral vectors have been
proposed, and the most popular consisted of fiber cap-
somere modifications, to allow the vectors to attach to
newly defined cell targets for efficient virus entry
[15,17,18].
A fiber-modified, ß-galactosidase (ß-gal)-expressing
adenoviral vector, originally called HAdV5-F2/BAdV4-
ßgal and abbreviated Ad5FB4 in the present study, was
previously constructed and characterized. Ad5FB4 is a
human adenovirus serotype 5 which carries chimeric,
human/bovine fibers [23-27]. It does not recognize the
ubiquitous hCAR, and binds to cells via an attachment
receptor different from the heparan sulfate proteogly-
cans [25]. Transduction of hCAR-negative and hCAR-
positive cells occurs via a clathrin-independent endocy-
tic pathway involving lipid raft/caveolae [27]. An advan-
tage of the altered tropism of the Ad5FB4 vector is the
restriction of its infection repertoire of cells, which
therefore limits the vector dissemination [24]. This
results in the reduction of adenovirus-associated
humoral and innate cytokine immune responses upon
intravenous administration of Ad5FB4 vector to mice
[26].
In the present study, we tested Ad5FB4 on malignant
cells refractory to conventional Ad5-based vectors, and
found that the permissiveness of murine leukemia cells
to Ad5FB4 correlated with their dormancy time and the
expression level of B7.1 and B7-H1 molecules at their
surface. Results from in vitro and in vivo experiments
suggested that B7.1 and B7-H1 molecules played differ-
ent roles in Ad5FB4-mediated transduction of murine
dormant leukemia cells, with B7.1 involved in cell
attachment of Ad5FB4, and B7-H1 in its cellular uptake.
Our data also suggested that the interaction between
B7.1 and Ad5FB4 was mediated by the penton capsome-
res (or penton base-linked fibers) of the vector capsid.
In situ BRET analysis showed that B7.1 interacted with
B7-H1 to form heterodimers at the cell surface, and that
Ad5FB4 penton capsomeres interfered negatively with
the formation of these complexes. Our finding that
tumor cell surface molecules of the B7 family implicated
in immunoevasion mechanisms were recognised by the
adenoviral vector Ad5FB4 offered novel opportunities
for cancer therapy, using intrinsically B7-targeted
Ad5FB4 vectors for therapeutic gene transfer. Alterna-
tively, Ad5FB4 penton capsomeres, via their negative
interference with the B7-H1/B7.1 heterodimer forma-
tion, might be used as therapeutic agents to decrease
the amounts of these complexes at the tumor cell sur-
face, and hence lower their capacity to resist to anti-
tumor T-cell responses.
Methods
Plasmids
Mouse B7-H1 cDNA was kindly provided by M. Azuma
[28], and pSelect-B7.1 was purchased from Invivogen
(San Diego, CA). For fusion constructs, the stop codons
of the murine coding sequences of B7-H1 and B7.1
were removed from the plasmids. PCR products were
cloned in phase with either Rluc8 or YPet into the
pcDNA3 vector [29].
Cell culture and transfection
Dormant leukemia cells (DA1-3b/d35, DA1-3b/d90 and
DA1-3b/d365) were established as described previously
[12]. DA1-3b and DA1-3b-derived cell lines, Raji and
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10% fetal bovine serum (FBS), 1% non-essential amino
acids (NEAA), and 1 mM sodium pyruvate. Epithelial
cells HEK-293 and A549 were cultured in DMEM med-
ium supplemented with 10% FBS and 1% NEAA. HeLa
cells were grown in DMEM supplemented with 10%
FBS, 4.5 g/L glucose, and 1 mM glutamine. Transfec-
tions for establishing transient expression were per-
formed using Fugene6 HD (Roche, Meylan, France).
Cells were maintained in a humidified incubator at 37°C
with 5% CO2.
Antibodies and immunodetection of cell surface
molecules. (i) B7-H1/B7.1
Cells (10
6-aliquots) were first incubated with 5 μg/mL
of Fc-receptor blocking antibody (rat anti-mouse
CD16/CD32; BD Biosciences, Le Pont-De-Claix,
France) for 5 min at 4°C. Cells were then reacted with
monoclonal antibodies against PE-labeled mouse/
human B7-H1, FITC-labeled mouse/human B7.1
(eBioscience, San Diego, CA; http://www.eBioscience.
com), and the corresponding control isotype, at 40 μg/
mL and 4°C for 1 h. Cell surface expression of B7-H1
or B7.1 was quantitated by flow cytometry, using an
EPICS XL MLC Coulter flow cytometer. For detection
of cell surface molecules B7.1 and B7-H1 after adeno-
viral vector cellular uptake, aliquots of DA1-3b/d365
cells in suspension (1.5 × 10
6) were incubated at 4°C
for 90 min with Ad5FB4 vector doses of 5,000 or
10,000 physical particles per cell (vp/cell) in serum-free
medium. Cells were then transferred to 37°C for 10
min to allow for vector internalization, and probed for
B7-H1 and B7.1 by flow cytometry, as described above.
(ii) CAR. CAR was detected by flow cytometry, using
polyclonal antibody against mouse CAR (Santa Cruz
Biotechnology, Cat.#sc-10313), or the corresponding
control isotype (goat IgG; Santa Cruz biotechnology,
Cat#sc-3887). (iii) IgFcR. Cell surface expression of
immunoglobulin Fc receptors was assessed by flow
cytometry, using rat anti-mouse CD16/CD32 (Fc recep-
tor blocking antibody; BD Biosciences, Le Pont-De-
Claix, France) or the corresponding control isotype,
and Alexa fluor
® 4 8 8 - l a b e l e dg o a ta n t i - r a tI g G( I n v i t r o -
gen, A11006), and quantitated by flow cytometry, using
an EPICS XL MLC Coulter flow cytometer.
Cell sorting
DA1-3b cells (10
7) were suspended in 3 mL of ice-cold
PBS containing 1% BSA and 2 mM EDTA, and incu-
bated with monoclonal PE-labeled antibody against B7-
H1 or control, irrelevant isotopic antibody, as described
above. DA1-3b cells expressing B7-H1 at low and high
levels, respectively, were sorted using an Epics Altra
Coulter cell sorter.
B7-H1/B7.1 siRNA knockdown
DA1-3b/d365 cells were transfected by electroporation
with siRNA (Thermo Fisher, Dharmacon technology,
Belgium) using 3.3 nmol/cell of siRNA against murine
B7-H1 (5’-CACAAUUCgAggAgACgUAUU-3’)o rB 7 . 1
(5’-gAAUUACUggCAUCAAUA-3’). Negative control
siRNA consisted of scramble sequences. B7-H1 or B7.1
expression was immunodetected as described above, and
the silencing effect determined at 24, 48, 96 and 144 h
after electroporation.
Adenovirus vector amplification and labeling
The genetic constructions of the E1-deleted adenoviral
vectors Ad5 and Ad5FB4 containing the ß-gal reporter
gene have been described previously [23,24]. In the chi-
meric Ad5FB4 fiber, the junction between human sero-
type 2 fiber (F2) and bovine serotype 4 (BAdV4) fiber
was situated in the shaft repeat 7 at the GKL (glycine-
lysine-leucine) motif, to generate the chimeric fiber F2/
BAdV4 [24], abbreviated FB4 in the present study. The
Ad5FB4 and Ad5 vectors were amplified and purified
following conventional protocols. Since Ad5FB4 had a
lower tropism for epithelial cells, compared to Ad5, it
was not possible to compare their infectious titers by
conventional plaque assays on HEK-293 cell monolayers.
Stocks of purified vectors were titrated by optical mea-
surement of the viral DNA concentration at 260 nm,
and the vector titer expressed as vp/mL. Fluorescent
labeling of vector particles with carboxyfluorescein suc-
cinimidyl ester (FAM; Invitrogen, Cergy-Pontoise,
France) was performed as previously described [27].
Adenovirus infection
Ad5FB4 and Ad5 infections were carried out as pre-
viously described [27], except for the virus inoculum
which was eliminated by low-speed centrifugation of the
infected cells (800 × g, 5 min) at 24 h post-infection
(pi). Cells were then resuspended in culture medium
with 4% FBS and maintained for an extra 48 h for mur-
ine cells, or an extra 24 h for human cells. The ß-gal
activity was determined using fluorescein-ß-D-galacto-
pyranoside or the colorimetric X-gal staining procedure
(Fisher scientific, Belgium), as previously described [24].
Vector-cell binding and internalization
Cell aliquots (1.5 × 10
6) were incubated at 4°C for 1 h in
suspension with FAM-labeled Ad5 or FAM-labeled
Ad5FB4 at 10
11 vp/mL in serum-free medium. Cells
were rinsed with PBS containing 1% BSA (PBS-BSA),
and cell-bound vector particles were quantitated using
flow cytometry (FACS). For internalization assays, cells
and vector were incubated at 4°C for 1 h, then trans-
ferred to 37°C and further incubated at this temperature
for different periods of time, ranging from 5 min to 2 h.
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15 min at 37°C with trypsin at 0.25% in 1 mM EDTA to
detach vector particles possibly sequestered at the cell
surface [30]. Cells were resuspended in PBS-BSA, and
the amounts of internalized vector were quantitated by
FACS analysis.
Surface plasmon resonance (SPR)
SPR analyses were carried out using a BIAcore 2000.
Recombinant mouse B7-H1, B7.1 and PD-1 were cova-
lently immobilized onto separate flow cells of a CM5
biosensor chip by amine coupling according to the man-
ufacturer’s instructions. As a reference, another flow-cell
surface was activated and deactivated. Protein samples
were diluted in HBS (0.01 M Hepes, pH 7.4; 0.15 M
NaCl; 0.005% P20), and the binding analyses were per-
formed at 25°C with HBS as running buffer. A flow rate
of 10 μL/min was used to inject B7-H1, B7-H2, B7.1
(R&D Systems Europe, Lille, France) and 20 μL/min to
inject viral proteins; all samples were run five times. For
vector particles analysis, SPR experiments (BIAcore
3000) were run on a CM4 sensorship at 5 μL/min using
HBS-N (GE-Healthcare) supplemented with 2 mM
CaCl2. Immobilisation of both B7.1 and B7-H1 was per-
formed by interaction of these ligands diluted at 1 μg/
mL in 10 mM sodium acetate buffer pH 4.2 on EDC-
NHS activated flow-cells for 10 min at room tempera-
ture. After ethanolamine deactivation, vector particles
were injected (1.10
10 vp in 25 μL of running buffer) and
the signal from the ligand flow-cells was automatically
subtracted from the background of an ethanolamine
deactivated EDC-NHS flow-cell.
Human B7.1, B7-H1 and PD-1 proteins and adenoviral
capsid proteins
Recombinant B7-1-Fc, B7-H1-Fc, and PD-1-Fc fusion
proteins used in SPR analyses were purchased from
R&D Systems. Adenovirus penton protein (penton base-
linked fiber) was isolated from adenovirus-infected 293
cell lysates, according to a conventional protocol
adapted to fast protein liquid chromatography [31-34].
BRET
At 24 h before transfection, cells (2 × 10
5-aliquots) were
plated in 6-well plates and transfected with increasing
amounts of B7.1-YPet-, B7-H1-YPet- or IR-YPet-expres-
sing plasmids (10 to 500 ng/well), and constant amounts
( 1 0n g - a l i q u o t s )o fp l a s m i de x p r e s s i n gB 7 - H 1 - R l u c 8o r
B7.1-Rluc8 fusion protein. 48 h later, cells were col-
lected and washed twice with PBS, and aliquots were
placed in 384-well plates. Coelenterazine H substrate
was added at a final molarity of 5 μM, and BRET was
measured immediately. To analyze the effect of the pen-
ton, cells were incubated for 5 min without or with
penton protein solution at 0.33, 0.66 or 132 ng/μL, fol-
lowed by Coelenterazine H addition and BRET measure-
ment. BRET was monitored using a lumino/fluorometer
(Mithras; Berthold Technologies, France), allowing for
the sequential integration of luminescence with two fil-
ter settings (Rluc filter, 485 ± 10 nm; YFP filter, 530 ±
12.5 nm). The emission signal values obtained at 530
nm were divided by the emission signal values obtained
at 485 nm. The BRET ratio was calculated by dividing
the emission signal value obtained with coexpressed
donor and acceptor by that obtained with the donor
protein expressed alone. Data from at least three inde-
pendent experiments were averaged, and results
expressed as milliBRET (mBRET), corresponding to the
BRET ratio multiplied by 1,000. Donor saturation curves
were determined as previously described [35,36].
Statistical analyses
Data were presented as the mean of triplicate experi-
ments (m ± SEM), and were representative of the results
obtained from three independent experiments that pro-
duced similar results. Statistical analyses were performed
using the Mann-Whitney test.
Results
Cell and vector nomenclature
Murine dormant leukemia cell lines have been previously
established from long-term persistent tumor cells isolated
from mice in a state of tumor dormancy [12,13]. In brief,
C3H/HeJ mice have been immunized with irradiated,
interleukin-12-treated or CD154-transduced DA1-3b
cells, challenged with parental DA1-3b cells, and ran-
domly sacrificed during a one-year follow-up period at
day 35, 90 and 365, respectively. Dormant leukemia cells
were collected from the spleen at these different times,
and the amount of BCR/ABL mRNA quantitatively
assayed using real-time PCR, leading to the following cell
lines: DA1-3b/d35, DA1-3b/d90 and DA1-3b/d365 [12].
The ß-gal-expressing, fiber-modified adenoviral vector
HAdV5-F2/BAdV4-ß-gal comprises of the human Ad5
DNA backbone containing a chimeric fiber gene. The
vector particle consisted of serotype 5 capsid carrying
chimeric fibers, each formed by the human serotype 2
fiber tail fused to the shaft and knob domains of bovine
serotype 4 (BAdV4) [23-27]. For reasons of simplifica-
tion, this human/bovine chimeric fiber vector was
referred to as Ad5FB4 in the present study, and the con-
trol, ß-gal-expressing Ad5 vector with homotypic sero-
type 5 capsid proteins was abbreviated Ad5.
Permissiveness of dormant leukemia cells to the chimeric
fiber vector Ad5FB4
The three cell lines DA1-3b/d35, DA1-3b/d90 and DA1-
3b/d365 were incubated with equal physical particle
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Ad5. The efficiency of cell transduction was assayed by
the percentage of ß-gal-positive cells and the level of ß-
gal expression, determined by the mean fluorescence
intensity (MFI) using a fluorescent ß-gal substrate. We
f o u n dt h a tA d 5 F B 4t r a n s d u c e dm u r i n ed o r m a n tl e u k e -
mia cells with a higher efficiency, compared to Ad5 vec-
tor (Figure 1A). Interestingly, the percentage of ß-gal-
positive cells was not not significantly different for the
various DA1-3b cell lines derived from in vivo passages.
Rather, the level of Ad5FB4-mediated transgene expres-
sion correlated with increased dormancy: the lowest ß-
gal activity was observed in DA1-3b/d35, the highest in
DA1-3b/d365 cells, with an intermediate value in DA1-
3b/d90 cells (Figure 1B). Of note, Ad5 transduction, as
determined by the percentage of transduced cells, also
correlated with the length of in vivo passage (Figure
1A). Interestingly, the transgene expression progressively
increased with the period of time after transduction, as
exemplified with Ad5FB4-transduced DA1-3b/d365
cells, which showed a 30-fold enhancement of ß-gal
activity between 72 and 120 h posttransduction (Figure
1C). These results suggested that the DA1-3b/d365 cells
provided a more favorable environment for the expres-
sion of the transgene transduced by Ad5FB4 or Ad5.
However, the possibility of an increased expression of
mouse CAR (mCAR) in the different cell lines, and/or
modifications of intracellular factors, e.g. transcription
factors, was envisaged. All cell lines were found to
express mCAR at their surface at various levels, as
assayed by flow cytometry (Figure 2A, B). The pattern
of mean fluorescence intensity in the different lines
roughly paralleled that of the percentage of mCAR-posi-
tive cells, and both data clearly showed no direct corre-
lation between mCAR levels, dormancy time and
increased Ad5 (or Ad5FB4) transduction.
Correlation between cell surface levels of B7-H1 and B7.1
molecules and cell permissiveness to Ad5FB4
The apparent correlation between the level of Ad5FB4-
mediated ß-gal expression and the dormancy time, as
shown in Figure 1B, suggested that the degree of per-
missiveness of DA1-3b cells to Ad5FB4 depended on
the level of expression of B7-H1 and B7.1 molecules at
the cell surface. To test this hypothesis, we analyzed the
permissiveness to Ad5FB4 of various mouse and human
cell lines differing by their absolute and relative levels of
surface-expressed B7-H1 and B7.1 (Figure 3A). We
found that the Ad5FB4-mediated cell transduction
required both B7.1 and B7-H1 molecules, but the trans-
duction efficiency seemed to correlate with the B7-H1
levels (Figure 3B).
Since intrinsic properties of individual cell lines could
influence the cell transduction levels independently of
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Figure 1 Correlation between the efficiency of Ad5FB4-
mediated transduction of murine dormant leukemia cells and
the time of tumor dormancy. (A, B), DA1-3b cells and the DA1-
3b-derived cell lines DA1-3b/35, DA1-3b/d90 and DA1-3b/d365
were incubated with ß-gal-expressing Ad5 (open square) or Ad5FB4
vector (black square) at 10
4 vp/cell for 2 h at 37°C in serum-free
medium. The ß-gal activity was evaluated by flow cytometry at 72 h
pi, and expressed as (A) the percentage of ß-gal-positive cells, or (B)
mean fluorescence intensity (MFI). In (B), the numbers on top of the
bars represented the fold enhancement of ß-gal activity relative to
the value in DA1-3b cells, which was attributed the 1-value. (C),
DA1-3b/d365 cells were incubated with Ad5-ßgal (open square) or
Ad5FB4-ßgal (black square) at 10
4 vp/cell for 2 h at 37°C, harvested
at different times pi as indicated on the x-axis, and assayed for ß-gal
expression. The ß-gal activity was expressed as MFI. Symbols: **, p <
0.01; ***, p < 0.001.
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Page 5 of 14the B7.1/B7-H1 pattern, we sorted the DA1-3b cell line
into two subpopulations, on the basis of their levels of
surface expression of the B7-H1 protein. The two sub-
clones isolated, referred to as DA1-3bLow and DA1-
3bHigh, respectively (Figure 3A), were assayed for ß-gal
activity after Ad5FB4 transduction. The results indicated
that the subpopulation of high B7-H1-expressors was
transduced with a 7-fold higher efficiency, compared to
the subpopulation of low B7-H1-expressors (Figure 3B).
This confirmed that the transduction efficiency by
Ad5FB4 correlated with the level of expression of the
B7-H1 protein and the ratio of B7-H1 to B7.1. Interest-
ingly, the fact that both the original DA1-3b and the
DA1-3bLow subclone were low expressors of B7-H1
and B7.1 but exhibited marked differences in ß-gal
expression (Figure 3B) suggested the existence of a
threshold of B7-H1 at which the influence on ß-gal
expression became apparent. This threshold was consis-
tent with a cooperative effect between B7-H1 and B7.1
for Ad5FB4 uptake, with B7-H1 being the limiting fac-
tor: a certain concentration of B7-H1 molecules would
be required to form B7.1-B7-H1 complexes at the cell
surface and mediate the cell entry of the vector, as
described below.
A similar correlation between permissiveness to
Ad5FB4 and B7.1/B7-H1 pattern was observed for
human cell lines Raji, Jurkat and A549 (Figure 3A, B).
Unfortunately, no control data could be provided using
mouse cell lines expressing only one or the other B7
molecule, since tumor dormancy was consistently asso-
ciated with the expression of both B7 products at the
cell surface. In the case of human cells however, we
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Figure 2 Cell surface expression of mouse CAR (mCAR) and
immunoglobulin Fc receptors in DA1-3b and DA1-3b-derived
cell lines. (A, B), CAR expression. Cells first incubated with Fc
receptor blocking antibody (rat anti-mouse CD16/CD32), or the
corresponding control isotype, were reacted with goat polyclonal
antibody against mCAR followed by FITC-labeled secondary
antibody (donkey anti-goat), and analyzed by flow cytometry.
Results are expressed as (A) the percentage of mCAR-positive cells,
and (B) MFI. The open bars in panels A and B correspond to the
isotype-matched control antibodies. (C), Fc receptors. Cells
incubated with Fc receptor blocking antibody (dotted line), or the
corresponding control isotype (solid line), as above, were reacted
with Alexa fluor
® 488-labeled goat anti-rat IgG. Results are
presented as conventional flow cytometry patterns.
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Figure 3 Permissiveness to Ad5FB4 and expression of B7
molecules at the surface of murine and human cells. (A), Cells
were reacted with PE-labeled antibody against murine or human
B7-H1 or B7.1, and analyzed by flow cytometry. Symbols (+++), (++),
(+), and (-) refer to the respective levels of surface expression of B7-
H1 and B7.1, evaluated by MFI, and expressed as arbitrary units (AU):
(-), undetectable; (+), 10-20; (++), 50-80; (+++), 200-300 AU. (B), Cells
were transduced by ß-gal-expressing Ad5FB4 vector at 10
4 vp/cell,
and ß-gal assayed at 72 h pi in murine cells, and at 48 h pi in
human cells. Symbols: ***, p < 0.001; (+++/+), (++/+), (+/+), (+/-)
and (-/+) refer to the respective levels of surface expression of B7-
H1/B7.1, as evaluated in panel (A).
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Page 6 of 14found no cell line that coexpresses B7-H1 and B7.1.
This was the reason why indirect methods, e.g. specific
RNA interference and single or double expression of B7
molecules via plasmid transfection, were used (Cf.
below).
Respective roles of B7.1 and B7-H1 molecules in the
cellular uptake of Ad5FB4
To determine whether B7.1 or/and B7-H1 could be used
by Ad5FB4 as receptors for attachment and/or entry
into murine cells, the method of choice would consist of
cell binding competition experiments between the vector
and (i) the soluble form of the candidate receptor(s),
and between the vector and (ii) the soluble ligands of
the candidate receptor(s). However, the recombinant B7
molecules available commercially consisted of the B7.1
and B7-H1 ectodomains fused to the immunoglobulin
(Ig) Fc domain (B7.1-Fc and B7-H1-Fc), and the same
was true for the natural ligand of B7-H1, Programmed
Death-1 (PD-1; [37]). Since the binding of the Fc-fused
proteins to Fc receptors present at the surface of all
DA1-3b cells (Figure 2B) would introduce a bias in the
competition assays with B7.1-Fc, B7-H1-Fc and PD-1-
Fc, we used alternative methods to assess the respective
roles of B7.1 and B7-H1 proteins in the cell permissive-
ness to Ad5FB4.
(i) B7.1 knockdown and Ad5FB4-cell binding
B7.1 gene silencing was performed in DA1-3b/d365
cells, using small interfering RNA (siRNA). The reduc-
tion of surface expression of B7.1 was found to be maxi-
mal at 96 h after siRNA electroporation, as assessed by
flow cytometry (Figure 4A). DA1-3b/d365 cells electro-
porated with siRNA were then transferred to 4°C, and
incubated with aliquots of FAM-labeled, fluorescent
Ad5FB4 particles for 90 min at 4°C. Cell-bound Ad5FB4
particles were quantitated by flow cytometry analysis of
the fluorescent signal. A significant reduction (ca. 50%)
in cell binding was observed in B7.1-siRNA-treated cells,
compared to control siRNA-treated cells (Figure 4B).
T h i ss u g g e s t e dt h a tB 7 . 1p l a y e dt h er o l eo fa t t a c h m e n t
receptor for Ad5FB4 at the surface of DA1-3b/d365
cells.
(ii) B7-H1 knockdown and cellular internalization of Ad5FB4
Specific siRNA was also used to decrease the surface
expression of B7-H1 (Figure 5A). After B7-H1 silencing,
there was no detectable change in the binding of FAM-
labeled Ad5FB4 to DA1-3b/d365 cells at low tempera-
ture (Figure 5B). For cell internalization assays, fluores-
cent-labeled Ad5FB4 particles were incubated with
DA1-3b/d365 cells at 4°C to allow for vector-cell attach-
ment, then samples transferred to 37°C. Vector particles
remaining trapped at the cell surface were removed by
digestion with trypsin [30], and the amounts of fluores-
cent-labeled Ad5FB4 particles internalized by DA1-3b/
d365 cells were measured by flow cytometry at different
times posttransfer to 37°C (5 to 120 min). The cell
transduction efficiency, measured by the ß-gal activity,
was also determined at vector doses, ranging from 500
to 10,000 vp/cell. The cellular internalization of Ad5FB4
was significantly reduced in B7-H1-silenced DA1-3b/
d365 cells at all time points, with a maximum 40% inhi-
bition at 60 min (Figure 5C). Likewise, the transduction
efficiency significantly decreased after B7-H1 knock-
down at all vector doses used: a maximum 50% inhibi-
t i o nw a so b s e r v e da t1 , 0 0 0t o2 , 0 0 0v p / c e l l ,b u tt h e
inhibitory effect almost plateaued at higher vector doses
(Figure 5D).
(iii) B7-mediated gain of viral receptor function by Ad5FB4-
refractory cells
We have shown in previous studies that HeLa cells have
a low permissiveness to Ad5FB4 infection [23-25,27].
Transfection of HeLa cells with one single plasmid
expressing B7.1 or B7-H1 protein alone did not show
any significant increase in their permissivity to Ad5FB4
(Figure 6, compare samples a, b and c). Of note, the
relatively high background of ß-gal expression in con-
trol, nontransfected cells (Figure 6a) was due to the fact
that HeLa cells are not totally refractory to Ad5FB4, as
already reported [23-25,27]. However, coexpression of
B7.1 and B7-H1 proteins by double transfection con-
ferred to HeLa cells a full permissiveness to Ad5FB4
(Figure 6d). Taken together, these results suggested that
the uptake of Ad5FB4 by HeLa cells and murine leuke-
mia cells DA1-3b/d365 required the coexpression of B7-
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Figure 4 Effect of B7.1 silencing on the Ad5FB4-DA1-3b/d365
cell binding. Cells were electroporated with control siRNA or siRNA
against B7.1 (3 nmol/cell), maintained in culture for 96 h, transferred
to 4°C, then incubated with FAM-labeled Ad5FB4 at 10
4 vp/cell for
90 min at 4°C. (A), The efficiency of B7.1 silencing was verified by
flow cytometry, using PE-labeled antibody against murine B7.1. (a),
control siRNA; (b), siRNA against B7.1; (c), control irrelevant isotypic
antibody. (B), Cell-bound Ad5FB4 vector particles were quantitated
by flow cytometry analysis of cell surface-associated fluorescent
signal, and results expressed as the percentage of positive,
fluorescent cells.
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Page 7 of 14H1 and B7.1 molecules at the cell surface. In addition,
the data with DA1-3b/d365 cells suggested that B7-H1
and B7.1 were involved in two different mechanisms:
B7.1 would be mainly responsible for cell attachment of
vector particles, while B7-H1 would contribute to their
internalization, and to the efficiency of vector-mediated
transduction.
In vitro interactions between B7.1, B7-H1, Ad5FB4, and
adenoviral capsid components
The possible interactions between the different recombi-
nant proteins B7-H1-Fc, B7.1-Fc and PD-1-Fc on one
hand, and between B7-H1-Fc or B7.1-Fc and Ad5FB4
vector on the other hand, were investigated using sur-
face plasmon resonance (SPR). SPR analysis confirmed
the interaction between B7-H1 and PD-1 already
reported [5]: the value for the KD (0.82 μM; Figure 7A)
was in good consistency with that previously determined
(KD =0 . 7 7μM; [5]). Our sensorgrams also confirmed
the interaction between B7-H1 and B7.1 recently
described [6]: the B7-H1-B7.1 binding reaction was
found to occur with KD values of 0.38 μMB 7 . 1o r1 . 0 7
μM B7-H1, when B7.1 and B7-H1 were alternatively
used as ligand or ligate (Figure 7B).
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Figure 5 Effect of B7-H1 silencing on cell binding and uptake
of Ad5FB4 by DA1-3b/d365 cells. (A, B), Ad5FB4-cell binding.
Cells were transfected with control siRNA or siRNA against B7-H1 (3
nmol/cell), and maintained in culture for 144 h. They were then
incubated with FAM-labeled Ad5FB4 at 10
4 vp/cell for 90 min at 4°
C. (A), The efficiency of B7-H1 silencing was verified by flow
cytometry analysis of siRNA-treated cells, using PE-labeled antibody
against murine B7-H1. Curves were: a, control siRNA; b, siRNA
against B7-H1; c, control irrelevant isotypic antibody. (B), Cell-bound
Ad5FB4 vector particles were quantitated by flow cytometry, and
results expressed as the percentage of positive, fluorescent cells. (C,
D), Cellular uptake and transduction. Cells were transfected with
control siRNA or siRNA to B7-H1 (3 nmol/cell) and maintained in
culture for 144 h. They were incubated with FAM-labeled Ad5FB4 at
10
4 vp/cell for 90 min at 4°C, followed by transfer to 37°C for
different periods of time, ranging from 5 to 120 min. (C), Cellular
internalization of Ad5FB4 particles. Intracellular vector was
quantitated by flow cytometry, and results expressed as the
percentage of positive, fluorescent cells. The numbers on top of the
rightmost series of bars represented the percentage of decrease in
the number of positive cells, relative to that number in control
siRNA-treated cell samples at time 0 of transfer to 37°C, which was
attributed the 100%-value. (D), Ad5FB4-mediated DA1-3b/d365 cell
transduction. B7-H1 siRNA-treated cells were taken at 144 h after
transfection and incubated with the Ad5FB4 vector for 2 h at 37°C
at increasing vector doses, ranging from 5 × 10
2 to 10
4 vp/cell.
After an additional 72 h at 37°C, ß-gal activity was assayed in cell
lysates, and expressed as MFI. The numbers on top of the rightmost
series of bars represented the decrease of ß-gal activity (as a
percentage of control), relative to the value in control siRNA-treated
cells infected with 5 × 10
2 vp/cell, which was attributed the 100%-
value. MOI, multiplicity of infection, expressed as vp/cell.
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Page 8 of 14SPR analysis, using immobilized B7.1-Fc and B7-H1-
Fc proteins, showed that Ad5FB4 vector particles inter-
acted directly with B7.1-Fc (Figure 7C), but not with
B7-H1-Fc (not shown). Purified penton protein, the ade-
noviral capsomere responsible for cell attachment and
endocytosis (reviewed in [17,18]), and consisting of pen-
ton base-linked fiber, was isolated from Ad5FB4-infected
HEK-293 cells as free, nonencapsidated viral protein
[31,33]. Samples of Ad5FB4 penton protein were assayed
by SPR on immobilized B7.1-Fc and B7-H1-Fc proteins.
Ad5FB4 penton interacted with B7.1-Fc, but not with
B7-H1-Fc (Figure 7D), suggesting that the binding of
Ad5FB4 particles to cell surface-displayed B7.1 mole-
cules occurred via their fiber apical projections [17,18].
Interestingly, when Ad5FB4 particles were preincu-
bated with the B7.1-Fc protein prior to injection onto
surface-immobilized B7-H1-Fc, no extra signal over the
basic signal of B7.1-B7-H1 interaction was detected on
the sensorgrams (data not shown), suggesting that the
binding of Ad5FB4 to B7.1 did not increase the affinity
of B7.1 to B7-H1. The next experiments were designed
to further explore the respective roles of B7.1 and B7-
H1 in the cell binding and entry of Ad5FB4 in the con-
text of the DA1-3b/d365 plasma membrane.
Cellular internalization of B7-H1 molecules upon Ad5FB4
uptake
DA1-3b/d365 cells in suspension were incubated with
Ad5FB4 vector particles for 90 min at 4°C, a tempera-
ture which allows cell attachment of the vector but
blocks its endocytosis. Cells were then transferred to 37°
C to induce the vector internalization, and the status of
B7.1 and B7-H1 molecules at the cell surface examined
by flow cytometry at 10-15 min after transfer. No modi-
fication of the B7.1 signal was detected upon Ad5FB4
endocytosis, even at high vector doses (10,000 vp/cell).
By contrast, a discrete but significant decrease was
observed in the levels of B7-H1 protein at the cell sur-
face upon Ad5FB4 uptake, and in a vector dose-depen-
dent manner: 15-17% at 5,000 vp/cell, and 22-25% at
10,000 vp/cell (Figure 8). However, the possibility
existed that cell-bound vector particles masked the epi-
tope of the B7-H1 molecules recognized by the specific
antibody used in flow cytometry, and biased the results.
To address this issue, cells were analyzed by flow cyto-
metry immediately after incubation with Ad5FB4 at 4°C.
The immunoreactivity of B7 molecules was found to be
similar at the surface of control cells without Ad5FB4
and cells incubated with Ad5FB4 at 4°C (Figure 8,
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Page 9 of 14compare open bars and grey bars). The data clearly
showed that the B7-H1 epitope was still accessible after
Ad5FB4-cell binding, and suggested a cointernalization
of B7-H1 molecules with Ad5FB4 particles. This sup-
ported the above-mentioned hypothesis that B7-H1
would be involved in Ad5FB4 endocytosis. In order to
further dissect the mechanism of cellular entry of the
Ad5FB4 vector and the contribution of the B7 molecules
in this pathway, interactions between B7.1, B7-H1 and
the adenoviral penton capsomeres were analyzed in situ
within the context of live cell plasma membrane, using
a recently developed enhancement of the biolumines-
cence resonance energy transfer (BRET) technique [29].
Fluorescence microscopic analysis of B7.1, B7-H1 and
Ad5FB4 interactions in situ
(i) Functionality of Rluc8- and YPet-fused B7-H1 and B7.1
molecules
B7.1 and B7-H1 proteins were fused to the Renilla luci-
ferase variant Rluc8 as the energy donor [38], or to the
YFP variant YPet (yellow fluorescent protein for energy
transfer) as the energy acceptor [39]. The functionality
of the resulting fusion proteins was monitored by their
ability to function as alternative adenovirus receptors
when overexpressed in HeLa cells, which were otherwise
refractory to Ad5FB4. We found that HeLa cells
cotransfected with plasmids expressing B7.1-Rluc8 and
B7-H1-YPet (Figure 6e), or alternatively B7.1-YPet and
B7-H1-Rluc8 (Figure 6f), were transduced by Ad5FB4
with the same efficiency as HeLa cells coexpressing
non-fused B7-H1 and B7.1 proteins (Figure 6d).
(ii) Interactions between B7.1 and B7-H1
The interactions of B7.1 and B7-H1 with themselves and
with each other were then analyzed by BRET, using B7-
H1 and B7.1 fusion proteins coexpressed in HeLa cells.
Donor saturation curves using B7.1 as donor (B7.1-
Rluc8) and B7.1 as acceptor (B7.1-YPet) showed a direct
interaction between B7.1 molecules (Figure 9A), con-
firming the occurrence of B7.1 homodimers at the cell
surface, as previously described [40,41]. Likewise, the
saturation curve of B7-H1 used as donor (B7-H1-Rluc8)
and B7-H1 used as acceptor (B7-H1-YPet), confirmed
the occurrence of B7-H1 homodimers (Figure 9B), as
already reported [41]. When B7.1-Rluc8 and B7-H1-
YPet were coexpressed as donor and acceptor, respec-
tively (Figure 9A), and in the opposite configuration of
B7-H1-Rluc8 with B7.1-YPet (Figure 9B), the two curves
of BRET response superimposed and plateaued at the
same value (ca. 800 mBRET), demonstrating the forma-
tion of B7.1/B7-H1 heterodimers. As a negative control,
the cell surface-expressed insulin receptor (IR) fused to
YPet (IR-YPet) and previously studied by BRET [42] did
not show any detectable interaction with B7.1 or B7-H1,
both used as the donor fusion proteins (Figure 9A, B).
(iii) Effect of Ad5FB4 on B7.1-B7-H1 interaction
We then applied the BRET analysis to explore the mole-
cular events implicated in, or resulting from, the binding
of Ad5FB4 to B7-H1/B7.1-expressing cells. When HeLa
cells coexpressing donor B7.1-Rluc8 and acceptor B7-
H1-YPet, as in the configuration of Figure 9A, were
incubated with increasing doses of Ad5FB4 vector parti-
cles, a modest effect in BRET signals was observed at
the highest dose of 10,000 vp/cell (not shown). We then
used Ad5FB4 penton protein, the components of the
adenoviral capsid responsible for cell attachment and
endocytosis [17,18]. The rationale for the use of penton
capsomeres instead of vector particles in BRET analysis
was based on the following arguments: (i) like adeno-
virus particles, penton capsomeres are capable of cell
attachment and entry [43-47]; (ii) in terms of macromo-
lecules, isolated capsomeres have a higher solubility and
dispersity compared to virus particles, of which suspen-
sions are prone to aggregate; (iii) there are 12 pentons
per adenoviral capsid, which represent ca. 5% of the
total protein content of the virion. Considering that 3.4
×1 0
12 adenovirus particles correspond to 1 mg protein
[48], a solution of penton protein at the concentration
of 132 ng/μL (the maximum concentration used in our
dose-dependent curves) would correspond to a theoreti-
cal number of 9 × 10
9 vp/μL, viz. as many as 45,000 vp/
cell in our standard BRET assays. Such high doses
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Figure 8 Cell surface status of B7 molecules upon Ad5FB4
internalization. DA1-3b/d365 cells in suspension were incubated
for 90 min at 4°C without (open bars) or with Ad5FB4 vector (filled
bars) at 5,000 or 10,000 vp/cell. Cells were transferred to 37°C to
allow for Ad5FB4 endocytosis and entry. The presence of B7-H1 and
B7.1 molecules at the cell surface was assessed by flow cytometry in
control cells (open bars), in cells taken after vector attachment at 4°
C (grey bars), and in cells taken after 10 min at 37°C (black bars).
Results shown are MFI. Symbols: *, p < 0.05.
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Page 10 of 14might provoke nondesired cytotoxic effects interfering
with the metabolism of the B7 proteins, and justified the
use of penton protein as opposed to vector particles.
HeLa cells coexpressing donor B7.1-Rluc8 and acceptor
B7-H1-YPet were incubated with increasing doses of
Ad5FB4 penton protein, with Ad5 penton used as the
control. Donor saturationc u r v e ss h o w e da nA d 5 F B 4
penton-dependent, dose-response decrease of the BRET
signal (Figure 9C), whereas control Ad5 penton did not
induce any change in the BRET signal, even at the maxi-
mum concentration of 132 ng/μL (Figure 9D).
The BRET data indicated that less B7.1/B7-H1 hetero-
dimers were present at the cell surface after contact
with Ad5FB4 penton, which suggested that the binding
of Ad5FB4 penton to B7.1 prevented the formation of
the B7.1/B7-H1 heterodimeric complexes, or/and that
the complexes dissociated upon Ad5FB4 penton interac-
tion. However, we could not exclude another mechan-
ism, which consisted of a conformational change within
the B7.1/B7-H1 complex upon Ad5FB4 penton binding.
This structural modification might result in (i) a reor-
ientation of the two partner proteins less favorable to
generate a BRET signal, or/and (ii) in an increased dis-
tance between the donor and acceptor moieties of the
two fusion proteins, without a complete dissociation of
the complex [36]. Whatever the molecular mechanism,
our BRET analysis demonstrated that a significant modi-
fication occurred in the B7.1-B7-H1 interaction or/and
Figure 9 BRET analysis of B7.1, B7-H1 and Ad5FB4 interactions in situ. (A, B), Interactions between B7.1 and B7-H1 molecules.
Homodimeric and heterodimeric interactions were monitored in transfected HeLa cells using BRET donor saturation assays. Both B7.1 and B7-H1
were fused to Rluc8 to act as energy donors, alternatively; B7.1 (black circle), B7-H1 (open circle), and IR (open square) were fused to YPet to act
as energy acceptors. Cells were cotransfected with plasmids expressing B7.1-Rluc8 or B7-H1-Rluc8 at constant dose, and with different doses of
the other YPet-fused interactors. Results, expressed as mean milliBRET values (mBRET), were plotted versus the values of the YPet-to-Rluc8 ratio.
(C, D), Effect of penton-HeLa cell interaction on B7.1-B7-H1 heterodimers. B7.1-RLuc8 and B7-H1-YPet were coexpressed in HeLa cells and the
BRET donor saturation curves were determined in the absence (basal BRET; open circle) or presence of increasing doses of penton protein, at 33
(light grey circle), 66 (dark grey circle), and 132 ng/μL (black circle), respectively. (C), Ad5FB4 penton; (D), Ad5 penton. Results, expressed as
mBRET, were plotted versus the values of the YPet-to-Rluc8 ratio. Each point of the curves represented the average of six independent
experiments (m ± SEM).
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Page 11 of 14in their three-dimensional conformation and respective
topology within the heterodimeric complex, upon
Ad5FB4 penton interaction with the cell surface.
Discussion
The interaction of adenovirus with host cells leading to
a productive infection and to viral progeny represents a
complex, multifactorial process which depends on both
viral and cellular functions. The cell permissiveness to
the virus is the result of a fine balance between intrinsic
and extrinsic factors, but the efficacy of the primary
event of virus-cell attachment is one major parameter
which conditions the subsequent steps, and notably the
cell entry of the virus and the transcription of its gen-
ome. In the present study, we showed that the efficiency
of cell transduction by the chimeric fiber-pseudotyped
Ad5FB4 vector depended on the coexpression of two
molecules of the B7 family, B7-H1 and B7.1, at the sur-
face of cells otherwise refractory or poorly permissive to
Ad5FB4. This was observed in both human cells and
murine dormant leukemia cells. Ad5FB4 efficiently
bound to and transduced DA1-3b/d365 leukemia cells, a
murine cell line derived from long-term dormant leuke-
mia cells which overexpressed B7-H1/B7.1 molecules.
Our data suggested that B7.1 was involved in Ad5FB4-
cell attachment, but both B7-H1 and B7.1 were required
for cell entry and efficient Ad5FB4-mediated transduc-
tion. BRET experiments demonstrated that B7-H1 and
B7.1 formed homodimers and also heterodimers at the
cell surface, and that B7-H1/B7.1 heterodimeric complex
formation was altered upon cell interaction with
Ad5FB4 penton capsomeres, the capsid components
which are responsible for the steps of vector-cell attach-
ment and entry. A tentative model for the cell attach-
ment and entry pathway of Ad5FB4 is presented in
Figure 10.
Under steady-state conditions, B7.1 is present as a
heterogenous population of monomers and noncovalent
dimers at the cell surface, and the same pattern has
been described for B7-H1 [40,41]. However, interaction
between B7-H1 and B7.1 molecules has also been
observed [41]. B7.1 has a relatively low affinity for B7-
H1 with, an intermediate affinity for CD28 and CTLA-4,
and a high affinity for PD-1. Using T-cells deficient for
different combinations of PD-1, B7.1, CD28 and CTLA-
4, Butte et al. found a bidirectional inhibitory interac-
tion between B7-H1 and B7.1 [6], with some overlap-
ping of the binding domains of B7.1 and PD-1 on the
B7-H1 molecule [6,9]. In the present study, we demon-
strated and confirmed the occurrence of B7-H1/B7.1
heterodimeric complexes in live cells.
Targeting the molecules of the B7 family is potentially
a promising strategy for cancer therapy for the following
reasons. (i) Dormant tumor cells have developed several
in vivo mechanisms to ensure their long-term persis-
tence in their hosts (reviewed in [13]). One of these
mechanisms is the overexpression of B7-H1 and B7.1,
which shields these cells from CTLs [10-12]. This sug-
gested that the equilibrium between minimal residual
disease and host immune response could be modified to
prevent disease recurrence. (ii) B7-H1 is frequently
observed in human cancers and has a prognostic role
for renal cell carcinoma [49]. (iii) B7-H1 and B7.1 play a
role in immunoevasion through their expression in den-
dritic cells present in tumor draining lymph nodes. The
delivery of various transgenes that may antagonize
immunoevasion mechanisms, such as the chemokine
CXCL10, which activates NK cells to kill B7-H1-overex-
pressing dormant leukemia cells [11], could help the
host in the clearance of the cancer cells.
In this context, our finding that Ad5FB4 acted as a
ligand of B7.1 monomer, and that Ad5FB4 penton nega-
tively interferred with B7.1/B7-H1 heterodimer forma-
tion, made Ad5FB4 a unique adenoviral vector for
cancer gene therapy, as it targeted cell surface molecules
involved in the immunoevasion mechanisms. In the light
of our observation in BRET analysis using Ad5FB4 pen-
ton protein, one could envisage to antagonize immunoe-
vasion mechanisms by using Ad5FB4 penton as
monovalent, single capsomeres, or as multivalent, dou-
ble chimeric dodecamers (or dodecahedrons) formed by
twelve penton base subunits of serotype 3 adenovirus
( A d 3 D d )l i n k e dt ot w e l v ec h i m e r i cF B 4f i b e r s
B7.1  
Extracellular 
medium 
(1)  (2) 
(3) 
(4) 
? 
Cytoplasm 
B7.1 
B7.1  B7-H1 
B7-H1 
B7.1 
B7-H1 
B7-H1 
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Ad5FB4  
Ad5FB4  
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Figure 10 Hypothetical model for the cell entry pathway of
Ad5FB4. Step 1: binding of Ad5FB4 to B7.1 monomer. Step 2: high
affinity interaction between B7-H1 and B7.1, and formation of a
B7.1-B7-H1 heterodimer. Step 3: conformational changes in B7.1 or/
and B7-H1, and possible modification of Ad5FB4-B7.1 interactions
(question mark, ?). Step 4: B7-H1-mediated endocytosis and
internalization of Ad5FB4. The data obtained in vitro (SPR) and in
vivo (cell binding assays and RNA interference) support the
mechanisms proposed for steps 1 and 2; the molecular events
depicted in step 3 are based on BRET analysis; the endocytic step 4
is supported by data of flow cytometry.
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Page 12 of 14(Ad3DdFB4). Ad3 dodecahedrons have been used as
efficient protein vectors to bind to and enter mamma-
lian cells [43-46]. It would be expected that Ad3DdFB4
would impair the formation of B7-H1/B7.1 heterodimers
in tumor cells, induce their dissociation, or would coin-
ternalize with one or the other molecule. The lower
expression of immunoevasion complexes at the cell sur-
face would in turn confer to tumor cells a higher sus-
ceptibility to tumor-reactive T-cells. Further
characterization of the interaction between chimeric
Ad3DdFB4 and B7-H1/B7.1 molecules in vitro and in
vivo will be necessary to optimize the conditions for
potential applications to cancer therapy.
Conclusions
Tumor cells express specific molecules at their surface
which may negatively affect their recognition by the
immune system. This is the case for proteins of the B7
family, which play important roles in the immunoeva-
sion of tumor cells. In the present study, we showed
that leukemia cells DA1-3b/d365 derived from long-
term dormant tumors, which are refractory to conven-
tional adenovirus serotype 5 (Ad5)-based vectors, were
permissive to Ad5FB4, an adenoviral vector carrying chi-
meric fibers. We found that the permissiveness of DA1-
3b/d365 cells to Ad5FB4 correlated with the level of
expression of B7.1 and B7-H1 molecules at their surface,
and that the permissivity to Ad5FB4 could be reverted
by RNA silencing of one or the other B7 gene transcript.
Results from in vitro and in vivo experiments suggested
that B7.1 and B7-H1 molecules played different roles in
Ad5FB4-mediated transduction of DA1-3b/d365 cells,
with B7.1 involved in Ad5FB4-cell attachment, and B7-
H1 in Ad5FB4 internalization. We showed that the
interaction between B7.1 and Ad5FB4 was mediated by
the penton protein, the capsid component carrying the
fiber projection. In situ BRET analysis showed that B7.1
and B7-H1 form heterodimeric complexes at the cell
surface, and that Ad5FB4 penton capsomeres interfered
negatively with the formation of B7.1/B7-H1 heterodi-
mers. Our observation that the adenoviral vector
Ad5FB4 interacted with cell surface molecules of the B7
family known to be implicated in immunoevasion
mechanisms offers novel opportunities for cancer ther-
apy using B7-H1/B7.1 heterodimers as cell surface tar-
gets, and Ad5FB4 vectors or Ad5FB4 penton
capsomeres as therapeutic agents. Two different strate-
gies might be envisaged: (i) naturally B7.1-targeted
Ad5FB4 vectors can be designed for transferring thera-
peutic genes to B7.1/B7-H1-overexpressing cells, (ii)
whereas soluble Ad5FB4 penton capsomeres would act
via their negative interference with the B7-H1/B7.1 het-
erodimer formation.
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